IDH2 and myelodysplastic syndrome: Preclinical studies demonstrated that enasidenib promoted AML cell differentiation via inhibition of IDH2 mutants and suppression of 2-HG production (Fig. 4).201 The first phase I/II trial of enasidenib is currently ongoing and interim results are promising for efficacy in AML/MDS patients with IDH2 mutations.